Eyes on Topical Ocular Disposition: The Considered Design of a Lead Janus Kinase (JAK) Inhibitor That Utilizes a Unique Azetidin-3-Amino Bridging Scaffold to Attenuate Off-Target Kinase Activity, While Driving Potency and Aqueous Solubility
Journal of Medicinal Chemistry · 2023
DOI: 10.1021/acs.jmedchem.3c00519 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2023. Verfasst von Heeren M Gordhan und 14 weiteren Autor:innen. Beteiligte Einrichtung: Alcon Research, LLC, Durham, North Carolina 27703, United States. Hauptthemen laut MEDLINE: Janus Kinase Inhibitors. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 61 Literaturangaben.
Abstract (Originalsprache)
An unmet medical need remains for patients suffering from dry eye disease (DED). A fast-acting, better-tolerated noncorticosteroid anti-inflammatory eye drop could improve patient outcomes and quality of life. Herein, we describe a small-molecule drug discovery effort to identify novel, potent, and water-soluble JAK inhibitors as immunomodulating agents for topical ocular disposition. A focused library of known 3-(4-(2-(arylamino)pyrimidin-4-yl)-1H-pyrazol-1-yl)propanenitriles was evaluated as a molecular starting point. Structure-activity relationships (SARs) revealed a ligand-efficient (LE) JAK inhibitor series, amenable to aqueous solubility. Subsequent in vitro analysis indicated the potential for off-target toxicity. A KINOMEscan selectivity profile of 5 substantiated the likelihood of widespread series affinity across the human kinome. An sp2-to-sp3 drug design strategy was undertaken to attenuate off-target kinase activity while driving JAK-STAT potency and aqueous solubility. Tactics to reduce aromatic character, increase fraction sp3 (Fsp3), and bolster molecular complexity led to the azetidin-3-amino bridging scaffold in 31.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Alcon Research, LLC, Durham, North Carolina 27703, United States.
- Sage Therapeutics, Inc., Boston, Massachusetts 02142, United States.
- ID Business Solutions, Ltd., Boston, Massachusetts 02210, United States.
- Baxter Healthcare Corp., Deerfield, Illinois 60015, United States.
ORCID-Profile: David A Ellis
Zitieren
APA
Gordhan, H. M., Miller, S. T., Clancy, D. C., Ina, M., McDougal, A. V., Cutno, D. K., Brown, R. V., Lichorowic, C. L., Sturdivant, J. M., Vick, K. A., Williams, S. S., deLong, M. A., White, J. C., Kopczynski, C. C., & Ellis, D. A. (2023). Eyes on Topical Ocular Disposition: The Considered Design of a Lead Janus Kinase (JAK) Inhibitor That Utilizes a Unique Azetidin-3-Amino Bridging Scaffold to Attenuate Off-Target Kinase Activity, While Driving Potency and Aqueous Solubility. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c00519
Vancouver
Gordhan HM, Miller ST, Clancy DC, Ina M, McDougal AV, Cutno DK, et al. Eyes on Topical Ocular Disposition: The Considered Design of a Lead Janus Kinase (JAK) Inhibitor That Utilizes a Unique Azetidin-3-Amino Bridging Scaffold to Attenuate Off-Target Kinase Activity, While Driving Potency and Aqueous Solubility. Journal of Medicinal Chemistry. 2023. doi:10.1021/acs.jmedchem.3c00519
BibTeX
@article{Gordhan2023,
author = {Gordhan, Heeren M and Miller, Steven T and Clancy, Daphne C and Ina, Maria and McDougal, Alan V and Cutno, D'Quan K and Brown, Robert V and Lichorowic, Cynthia L and Sturdivant, Jill M and Vick, Kyle A and Williams, Stuart S and deLong, Mitchell A and White, Jeffrey C and Kopczynski, Casey C and Ellis, David A},
title = {Eyes on Topical Ocular Disposition: The Considered Design of a Lead Janus Kinase (JAK) Inhibitor That Utilizes a Unique Azetidin-3-Amino Bridging Scaffold to Attenuate Off-Target Kinase Activity, While Driving Potency and Aqueous Solubility},
journal = {Journal of Medicinal Chemistry},
year = {2023},
doi = {10.1021/acs.jmedchem.3c00519}
}
EUVIMED